Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

An update on obtaining and enforcing therapeutic antibody patent claims

Nature Biotechnology volume 34, pages 1242–1244 (2016)Cite this article

Subjects

Therapeutic antibody patent owners face continuing challenges trying to obtain broad patents and enforce them in the United States and Europe.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sandercock, C.G. & Storz, U. Nat. Biotechnol. 30, 615–618 (2012).

    Article  CAS  Google Scholar 

  2. Biogen Idec., Inc. and Genentech, Inc. v. GlaxoSmithKline., LLC, et al., 713 F.3d 1090 (Fed. Cir. 2013).

  3. AbbVie Deutschland GmbH & Co., et al. v. Janssen Biotech, Inc. and Centocor Biologics, LLC, 759 F.3d 1285, 1289–90, 1294 (Fed. Cir. 2014).

  4. UCB, Inc., v. Yeda Research and Development Co., Ltd., 2015 WL 4619996 at *1, 117 F.Supp.3d 755 (E.D. Va. July 15, 2015), affirmed, Appeal 2015–1957, (Fed. Cir., Sept. 8, 2016).

  5. See, Amgen, Inc. et al. v. Sanofi-Aventis U.S. LLC et al., No. 14–01317-SLR, 2016 slip op. (D. Del. March 16, 2016).

Download references

Acknowledgements

The discussion herein represents the personal views of the authors and not the views of either the authors' firms or their clients.

Author information

Authors and Affiliations

  1. Theresa Gresl is at the International Maize and Wheat Improvement Center (CIMMYT), El Batán, Texcoco, Mexico,

    Theresa Gresl

  2. Ulrich Storz is at Michalski Hüttermann & Partner in Düsseldorf, Germany,

    Ulrich Storz

  3. Colin Sandercock is at Perkins Coie LLP, Washington, DC, USA.,

    Colin Sandercock

Authors
  1. Theresa Gresl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Storz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Colin Sandercock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Storz.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gresl, T., Storz, U. & Sandercock, C. An update on obtaining and enforcing therapeutic antibody patent claims. Nat Biotechnol 34, 1242–1244 (2016). https://doi.org/10.1038/nbt.3735

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3735

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing